Showing 1801-1810 of 5771 results for "".
- Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopiahttps://modernod.com/news/eyenovia-announces-first-patient-enrolled-in-phase-3-vision-2-trial-of-microline-for-presbyopia/2480400/Eyenovia announced that the first patient has been enrolled in the company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in presbyopia, known as VISION-2. “Following the co
- Aldeyra Therapeutics Announces Achievement of Primary Endpoint in Phase 2 Clinical Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-in-phase-2-clinical-trial-in-dry-eye-disease/2480392/Aldeyra Therapeutics announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% re
- Ocular Therapeutix to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-data-at-the-american-academy-of-ophthalmology-aao-2021-virtual-annual-meeting/2480384/Ocular Therapeutix announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12-15, 2021. “We are happy to have a large presence at AAO this year with six poster presentations in five different indicatio
- Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDAhttps://modernod.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device com
- Luminopia Announces FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eyehttps://modernod.com/news/luminopia-announces-fda-approval-of-digital-therapeutic-to-improve-vision-in-children-with-lazy-eye/2480369/Luminopia announced that the FDA has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children. Luminopia One is indicated for improvement in visual acuity in child
- Opus Genetics Announces Two Leadership Appointmentshttps://modernod.com/news/opus-genetics-announces-two-leadership-appointments/2480367/Opus Genetics announced two key appointments to its founding executive team. Ash Jayagopal, PhD, has joined the company as Chief Scientific Officer (CSO); and Joe Schachle has joined as Chief Operating Officer (COO). “We were thrilled to launch Opus last month to advance an A
- Sight Sciences Announces TearCare Clinical Data Published in Corneahttps://modernod.com/news/sight-sciences-announces-tearcare-clinical-data-published-in-cornea/2480366/Sight Sciences announced publication in the journal
- Hanita Lenses Launches New Website as Part of 40th Anniversaryhttps://modernod.com/news/hanita-lenses-launches-new-website-as-part-of-40th-anniversary/2480365/Hanita Lenses has marked its 40th anniversary by launching a new website as part of its rebranding. Israel-based Hanita Lenses is a manufacturer and provider of intraocular lens solutions for cataract surgery.
- SIFI Announces Positive Topline Results of the Pivotal Phase 3 Study of Polihexanide for the Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-announces-positive-topline-results-of-the-pivotal-phase-3-study-of-polihexanide-for-the-treatment-of-acanthamoeba-keratitis/2480362/SIFI annou
- MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platformhttps://modernod.com/news/meiragtx-announces-the-presentation-of-two-novel-inherited-retinal-disease-ird-programs-and-riboswitch-gene-regulation-platform/2480359/MeiraGTx announced three poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress. Two preclinical programs addressing inherited retinal diseases (IRDs) caused by mutations in KCNV2 and GUCY2D are presented with